{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:35:50Z","timestamp":1790516150714,"version":"4.1.0"},"reference-count":106,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Splenic marginal zone lymphoma (SMZL) is a small B-cell lymphoma, which has been recognized as a distinct pathological entity since the WHO 2008 classification. It classically presents an indolent evolution, but a third of patients progress rapidly and require aggressive treatments, such as immuno-chemotherapy or splenectomy, with all associated side effects. In recent years, advances in the comprehension of SMZL physiopathology have multiplied, thanks to the arrival of new devices in the panel of available molecular biology techniques, allowing the discovery of new molecular findings. In the era of targeted therapies, an update of current knowledge is needed to guide future researches, such as those on epigenetic modifications or the microenvironment of these lymphomas.<\/jats:p>","DOI":"10.3390\/curroncol28050297","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T10:59:12Z","timestamp":1630925952000},"page":"3430-3447","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["New Insights into the Biology and Diagnosis of Splenic Marginal Zone Lymphomas"],"prefix":"10.3390","volume":"28","author":[{"given":"Marie","family":"Donzel","sequence":"first","affiliation":[{"name":"Institut de pathologie multi-sites, H\u00f4pital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Baseggio","sequence":"additional","affiliation":[{"name":"Laboratoire d\u2019h\u00e9matologie, H\u00f4pital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre B\u00e9nite, France"},{"name":"INSERM-Unit\u00e9 Mixte de Recherche 1052 CNRS 5286, Team \u201cClinical and Experimental Models of Lymphomagenesis\u201d, UCBL, Cancer Research Center of Lyon, Universit\u00e9 Lyon, 69001 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Fontaine","sequence":"additional","affiliation":[{"name":"Institut de pathologie multi-sites, H\u00f4pital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Pesce","sequence":"additional","affiliation":[{"name":"Institut de pathologie multi-sites, H\u00f4pital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[{"name":"INSERM-Unit\u00e9 Mixte de Recherche 1052 CNRS 5286, Team \u201cClinical and Experimental Models of Lymphomagenesis\u201d, UCBL, Cancer Research Center of Lyon, Universit\u00e9 Lyon, 69001 Lyon, France"},{"name":"Service d\u2019h\u00e9matologie, H\u00f4pital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[{"name":"INSERM-Unit\u00e9 Mixte de Recherche 1052 CNRS 5286, Team \u201cClinical and Experimental Models of Lymphomagenesis\u201d, UCBL, Cancer Research Center of Lyon, Universit\u00e9 Lyon, 69001 Lyon, France"},{"name":"Service d\u2019h\u00e9matologie, H\u00f4pital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Verney","sequence":"additional","affiliation":[{"name":"INSERM-Unit\u00e9 Mixte de Recherche 1052 CNRS 5286, Team \u201cClinical and Experimental Models of Lymphomagenesis\u201d, UCBL, Cancer Research Center of Lyon, Universit\u00e9 Lyon, 69001 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Traverse-Glehen","sequence":"additional","affiliation":[{"name":"Institut de pathologie multi-sites, H\u00f4pital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre B\u00e9nite, France"},{"name":"INSERM-Unit\u00e9 Mixte de Recherche 1052 CNRS 5286, Team \u201cClinical and Experimental Models of Lymphomagenesis\u201d, UCBL, Cancer Research Center of Lyon, Universit\u00e9 Lyon, 69001 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic Marginal Zone Lymphoma: From Genetics to Management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.leukres.2016.03.005","article-title":"Splenic Marginal Zone Lymphoma: Prognostic Factors, Role of Watch and Wait Policy, and Other Therapeutic Approaches in the Rituximab Era","volume":"44","author":"Perrone","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_3","first-page":"405","article-title":"Splenic Marginal Zone Lymphoma: Excellent Outcomes in 64 Patients Treated in the Rituximab Era","volume":"22","author":"Starr","year":"2017","journal-title":"Hematol. Amst. Neth."},{"key":"ref_4","unstructured":"(2020, December 02). Risk Stratification for Splenic Marginal Zone Lymphoma Based on Haemoglobin Concentration, Platelet Count, High Lactate Dehydrogenase Level and Extrahilar Lymphadenopathy: Development and Validation on 593 Cases\u2013PubMed, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/22924582\/."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3109\/10428194.2013.818143","article-title":"Simplification of Risk Stratification for Splenic Marginal Zone Lymphoma: A Point-Based Score for Practical Use","volume":"55","author":"Montalban","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/CCO.0b013e328349ab8d","article-title":"Splenic Marginal Zone B-Cell Lymphoma: A Distinct Clinicopathological and Molecular Entity. Recent Advances in Ontogeny and Classification","volume":"23","author":"Baseggio","year":"2011","journal-title":"Curr. Opin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"v441","DOI":"10.1093\/annonc\/mdz251.019","article-title":"Splenic Marginal Zone Lymphoma: Clinical Characteristics and Prognostic Factors in a Series of 52 Patients","volume":"30","author":"Topcuoglu","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajh.20157","article-title":"Monoclonal Gammopathy in Extranodal Marginal Zone Lymphoma (ENMZL) Correlates with Advanced Disease and Bone Marrow Involvement","volume":"77","author":"Asatiani","year":"2004","journal-title":"Am. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal Zone Lymphomas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.seminhematol.2010.01.004","article-title":"Treatment of Splenic Marginal Zone Lymphoma: Splenectomy Versus Rituximab","volume":"47","author":"Bennett","year":"2010","journal-title":"Semin. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/bjh.17577","article-title":"Superior Outcome for Splenectomised Patients in a Population-based Study of Splenic Marginal Zone Lymphoma in Sweden","volume":"194","author":"Sima","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable Ibrutinib Responses in Relapsed\/Refractory Marginal Zone Lymphoma: Long-Term Follow-up and Biomarker Analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Bertoni, F., Rossi, D., and Zucca, E. (2018). Recent Advances in Understanding the Biology of Marginal Zone Lymphoma. F1000Research, 7.","DOI":"10.12688\/f1000research.13826.1"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/PPO.0000000000000463","article-title":"Marginal Zone Lymphomas","volume":"26","author":"Bertoni","year":"2020","journal-title":"Cancer J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.3324\/haematol.2016.161711","article-title":"Clinical and Diagnostic Relevance of NOTCH2 -and KLF2 -Mutations in Splenic Marginal Zone Lymphoma","volume":"102","author":"Cereceda","year":"2017","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e558","DOI":"10.3324\/haematol.2018.214957","article-title":"Novel Insights into the Genetics and Epigenetics of MALT Lymphoma Unveiled by next Generation Sequencing Analyses","volume":"104","author":"Cascione","year":"2019","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.11635","article-title":"NOTCH2 Mutations in Marginal Zone Lymphoma","volume":"93","author":"Wlodarska","year":"2008","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3109\/10428194.2016.1173212","article-title":"Genetic Aberrations in Small B-Cell Lymphomas and Leukemias: Molecular Pathology, Clinical Relevance and Therapeutic Targets","volume":"57","author":"Bogusz","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Gautam, A., Sreedharanunni, S., Sachdeva, M.U.S., Rana, S., Kashyap, D., Bose, P., Bal, A., Prakash, G., Malhotra, P., and Das, R. (2021). The Relative Expression Levels of CD148 and CD180 on Clonal B Cells and CD148\/CD180 Median Fluorescence Intensity Ratios Are Useful in the Characterization of Mature B Cell Lymphoid Neoplasms Infiltrating Blood and Bone Marrow\u2014Results from a Single Centre Pilot Study. Int. J. Lab. Hematol.","DOI":"10.1111\/ijlh.13467"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/cyto.b.21325","article-title":"CD180 Expression in B-Cell Lymphomas: A Multicenter GEIL Study: CD180 EXPRESSION IN B-CELL LYMPHOMAS","volume":"90","author":"Guy","year":"2016","journal-title":"Cytometry B Clin. Cytom."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1038\/leu.2013.3","article-title":"Cell-Surface Expression of the TLR Homolog CD180 in Circulating Cells from Splenic and Nodal Marginal Zone Lymphomas","volume":"27","author":"Miguet","year":"2013","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/sj.leu.2405068","article-title":"Splenic Marginal Zone Lymphoma Proposals for a Revision of Diagnostic, Staging and Therapeutic Criteria","volume":"22","author":"Matutes","year":"2008","journal-title":"Leukemia"},{"key":"ref_23","first-page":"191","article-title":"Splenectomy\u2014A Therapeutic Option in Splenic Marginal Zone Cell Lymphoma","volume":"47","author":"Ciufu","year":"2009","journal-title":"Rom. J. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3324\/haematol.2009.011049","article-title":"CD5 Expression Identifies a Subset of Splenic Marginal Zone Lymphomas with Higher Lymphocytosis: A Clinico-Pathological, Cytogenetic and Molecular Study of 24 Cases","volume":"95","author":"Baseggio","year":"2010","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1111\/ijlh.12824","article-title":"Usefulness of CD200 in the Differential Diagnosis of SDRPL, SMZL, and HCL","volume":"40","author":"Favre","year":"2018","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Watkins, A.J., Hamoudi, R.A., Zeng, N., Yan, Q., Huang, Y., Liu, H., Zhang, J., Braggio, E., Fonseca, R., and de Leval, L. (2012). An Integrated Genomic and Expression Analysis of 7q Deletion in Splenic Marginal Zone Lymphoma. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0044997"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/path.2665","article-title":"Splenic Marginal Zone Lymphoma: Characterization of 7q Deletion and Its Value in Diagnosis","volume":"220","author":"Watkins","year":"2010","journal-title":"J. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2141.2012.09226.x","article-title":"High-Throughput Sequencing Analysis of the Chromosome 7q32 Deletion Reveals IRF5 as a Potential Tumour Suppressor in Splenic Marginal-Zone Lymphoma","volume":"158","author":"Fresquet","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1182\/blood-2010-02-267476","article-title":"Cytogenetic Aberrations and Their Prognostic Value in a Series of 330 Splenic Marginal Zone B-Cell Lymphomas: A Multicenter Study of the Splenic B-Cell Lymphoma Group","volume":"116","author":"Salido","year":"2010","journal-title":"Blood"},{"key":"ref_30","first-page":"568","article-title":"Cytogenetics in the Management of Lymphomas and Lymphoproliferative Disorders in Adults and Children: An Update by the Groupe Francophone de Cytog\u00e9n\u00e9tique H\u00e9matologique (GFCH)","volume":"74","author":"Lefebvre","year":"2016","journal-title":"Ann. Biol. Clin."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1097\/01.MP.0000095895.19756.77","article-title":"Splenic Marginal Zone Lymphomas Presenting with Splenomegaly and Typical Immunophenotype Are Characterized by Allelic Loss in 7q31-32","volume":"16","author":"Boonstra","year":"2003","journal-title":"Mod. Pathol."},{"key":"ref_32","first-page":"241","article-title":"Splenic Marginal Zone Lymphoma: 7q Abnormalities","volume":"115","author":"Ibbotson","year":"2005","journal-title":"Methods Mol. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Robledo, C., Garc\u00eda, J.L., Benito, R., Flores, T., Mollejo, M., Mart\u00ednez-Climent, J.\u00c1., Garc\u00eda, E., Guti\u00e9rrez, N.C., Piris, M.A., and Hern\u00e1ndez, J.M. (2011). Molecular Characterization of the Region 7q22.1 in Splenic Marginal Zone Lymphomas. PloS ONE, 6.","DOI":"10.1371\/journal.pone.0024939"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood.V99.4.1299","article-title":"Analysis of the IGVH Somatic Mutations in Splenic Marginal Zone Lymphoma Defines a Group of Unmutated Cases with Frequent 7q Deletion and Adverse Clinical Course","volume":"99","author":"Algara","year":"2002","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/1078-0432.CCR-15-1170","article-title":"An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors","volume":"22","author":"Bikos","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/his.12092","article-title":"Immunoarchitectural Patterns in Splenic Marginal Zone Lymphoma: Correlations with Chromosomal Aberrations, IGHV Mutations, and Survival. A Study of 76 Cases","volume":"62","author":"Bachy","year":"2013","journal-title":"Histopathology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.3324\/haematol.2014.107680","article-title":"A Restricted IGHV Gene Repertoire in Splenic Marginal Zone Lymphoma Is Associated with Autoimmune Disorders","volume":"99","author":"Brisou","year":"2014","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.2010.025437","article-title":"Stereotyped Patterns of B-Cell Receptor in Splenic Marginal Zone Lymphoma","volume":"95","author":"Zibellini","year":"2010","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2012.3","article-title":"Over 30% of Patients with Splenic Marginal Zone Lymphoma Express the Same Immunoglobulin Heavy Variable Gene: Ontogenetic Implications","volume":"26","author":"Bikos","year":"2012","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/blood-2011-03-341651","article-title":"Splenic Marginal Zone Lymphoma with VH1-02 Gene Rearrangement Expresses Poly- and Self-Reactive Antibodies with Similar Reactivity","volume":"118","author":"Warsame","year":"2011","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.leu.2402073","article-title":"Molecular Heterogeneity of Splenic Marginal Zone Lymphomas: Analysis of Mutations in the 5\u2032 Non-Coding Region of the Bcl-6 Gene","volume":"15","author":"Mateo","year":"2001","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/modpathol.2012.220","article-title":"Splenic Marginal Zone Lymphoma: Comprehensive Analysis of Gene Expression and MiRNA Profiling","volume":"26","author":"Arribas","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/sj.leu.2404853","article-title":"MicroRNA Losses in the Frequently Deleted Region of 7q in SMZL","volume":"21","author":"Mollejo","year":"2007","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Artemaki, P.I., Letsos, P.A., Zoupa, I.C., Katsaraki, K., Karousi, P., Papageorgiou, S.G., Pappa, V., Scorilas, A., and Kontos, C.K. (2021). The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas. Biomedicines, 9.","DOI":"10.3390\/biomedicines9040333"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2141.2011.08848.x","article-title":"MicroRNA Expression Profile in Splenic Marginal Zone Lymphoma: Correspondence","volume":"156","author":"Bouteloup","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1365-2141.2008.07077.x","article-title":"Detection of Elevated Levels of Tumour-Associated MicroRNAs in Serum of Patients with Diffuse Large B-Cell Lymphoma","volume":"141","author":"Lawrie","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1365-2141.2008.07237.x","article-title":"MicroRNA Signatures Characterize Diffuse Large B-Cell Lymphomas and Follicular Lymphomas","volume":"142","author":"Roehle","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"10444","DOI":"10.1038\/s41598-019-46906-1","article-title":"Systematic Review of Somatic Mutations in Splenic Marginal Zone Lymphoma","volume":"9","author":"Parker","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1182\/blood-2011-06-359166","article-title":"Alteration of BIRC3 and Multiple Other NF\u039aB Pathway Genes in Splenic Marginal Zone Lymphoma","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semcancer.2016.08.002","article-title":"NF\u039aB Deregulation in Splenic Marginal Zone Lymphoma","volume":"39","author":"Spina","year":"2016","journal-title":"Semin. Cancer Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3324\/haematol.2011.054080","article-title":"BCR and TLR Signaling Pathways Are Recurrently Targeted by Genetic Changes in Splenic Marginal Zone Lymphomas","volume":"97","author":"Yan","year":"2012","journal-title":"Haematologica"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/PAS.0000000000000523","article-title":"NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-Cell Lymphoma Are Associated With Progressive Disease","volume":"40","author":"Martinez","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1084\/jem.20120910","article-title":"Whole-Genome Sequencing Identifies Recurrent Somatic NOTCH2 Mutations in Splenic Marginal Zone Lymphoma","volume":"209","author":"Kiel","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20120904","article-title":"The Coding Genome of Splenic Marginal Zone Lymphoma: Activation of NOTCH2 and Other Pathways Regulating Marginal Zone Development","volume":"209","author":"Rossi","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Peveling-Oberhag, J., Wolters, F., D\u00f6ring, C., Walter, D., Sellmann, L., Scholtysik, R., Lucioni, M., Schubach, M., Paulli, M., and Biskup, S. (2015). Whole Exome Sequencing of Microdissected Splenic Marginal Zone Lymphoma: A Study to Discover Novel Tumor-Specific Mutations. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1766-z"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/bloodadvances.2020002995","article-title":"Notch Activation Is Pervasive in SMZL and Uncommon in DLBCL: Implications for Notch Signaling in B-Cell Tumors","volume":"5","author":"Shanmugam","year":"2021","journal-title":"Blood Adv."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Parry, M., Rose-Zerilli, M.J.J., Gibson, J., Ennis, S., Walewska, R., Forster, J., Parker, H., Davis, Z., Gardiner, A., and Collins, A. (2013). Whole Exome Sequencing Identifies Novel Recurrently Mutated Genes in Patients with Splenic Marginal Zone Lymphoma. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083244"},{"key":"ref_58","first-page":"89","article-title":"The (Epi)Genomic Landscape of Splenic Marginal Zone Lymphoma, Biological Implications, Clinical Utility, and Future Questions","volume":"5","author":"Oquendo","year":"2021","journal-title":"J. Transl. Genet. Genom."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/leu.2014.330","article-title":"KLF2 Mutation Is the Most Frequent Somatic Change in Splenic Marginal Zone Lymphoma and Identifies a Subset with Distinct Genotype","volume":"29","author":"Clipson","year":"2015","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3324\/haematol.2016.160192","article-title":"Exome Sequencing Identifies Recurrent BCOR Alterations and the Absence of KLF2, TNFAIP3 and MYD88 Mutations in Splenic Diffuse Red Pulp Small B-Cell Lymphoma","volume":"102","author":"Jallades","year":"2017","journal-title":"Haematologica"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-14-2759","article-title":"Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing","volume":"21","author":"Parry","year":"2015","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_62","first-page":"252318","article-title":"CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma","volume":"2013","author":"Warsame","year":"2013","journal-title":"ISRN Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/leu.2013.365","article-title":"Whole-Exome Sequencing in Splenic Marginal Zone Lymphoma Reveals Mutations in Genes Involved in Marginal Zone Differentiation","volume":"28","author":"Almaraz","year":"2014","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1182\/blood.V124.21.5399.5399","article-title":"Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma in the Bone Marrow: Paratrabecular Involvement As an Important Distinguishing Feature","volume":"124","author":"Bassarova","year":"2014","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/modpathol.2014.120","article-title":"MYD88 L265P Mutation Analysis Helps Define Nodal Lymphoplasmacytic Lymphoma","volume":"28","author":"Hamadeh","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/PAS.0000000000000411","article-title":"MYD88 (L265P) Somatic Mutation in Marginal Zone B-Cell Lymphoma","volume":"39","author":"Mollejo","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle Cell Lymphoma: 2019 Update on the Diagnosis, Pathogenesis, Prognostication, and Management","volume":"94","author":"Jain","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3324\/haematol.2013.098574","article-title":"ATM Mutation Rather than BIRC3 Deletion and\/or Mutation Predicts Reduced Survival in 11q-Deleted Chronic Lymphocytic Leukemia: Data from the UK LRF CLL4 Trial","volume":"99","author":"Forster","year":"2014","journal-title":"Haematologica"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3324\/haematol.2019.219550","article-title":"Biological and Clinical Implications of BIRC3 Mutations in Chronic Lymphocytic Leukemia","volume":"105","author":"Diop","year":"2020","journal-title":"Haematologica"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13578-020-00521-0","article-title":"BIRC3 and BIRC5: Multi-faceted Inhibitors in Cancer","volume":"11","author":"Frazzi","year":"2021","journal-title":"Cell Biosci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1182\/blood-2008-08-174110","article-title":"The NF\u039aB Negative Regulator TNFAIP3 (A20) Is Inactivated by Somatic Mutations and Genomic Deletions in Marginal Zone Lymphomas","volume":"113","author":"Novak","year":"2009","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/leu.2014.294","article-title":"The Kr\u00fcppel-like Factor 2 Transcription Factor Gene Is Recurrently Mutated in Splenic Marginal Zone Lymphoma","volume":"29","author":"Piva","year":"2015","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fonc.2018.00550","article-title":"The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies","volume":"8","author":"Arruga","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2141.2011.08980.x","article-title":"Absence of NOTCH1 Gene Mutations in MALT Lymphomas: Correspondence","volume":"157","author":"Mensah","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood-2014-08-596247","article-title":"DNA Methylation Profiling Identifies Two Splenic Marginal Zone Lymphoma Subgroups with Different Clinical and Genetic Features","volume":"125","author":"Arribas","year":"2015","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The Tumour Microenvironment in B Cell Lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrc1409","article-title":"MALT Lymphoma: From Morphology to Molecules","volume":"4","author":"Isaacson","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1038\/bcj.2017.28","article-title":"Prevalence of Hepatitis B and Hepatitis C Viral Infections in Various Subtypes of B-Cell Non-Hodgkin Lymphoma: Confirmation of the Association with Splenic Marginal Zone Lymphoma","volume":"7","author":"Xiong","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13000-018-0750-8","article-title":"PD1hi Cells Associate with Clusters of Proliferating B-Cells in Marginal Zone Lymphoma","volume":"13","author":"Wickenden","year":"2018","journal-title":"Diagn. Pathol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"23589","DOI":"10.18632\/oncotarget.25283","article-title":"Toll-like Receptor Expression and Function Differ between Splenic Marginal Zone B Cell Lymphoma and Splenic Diffuse Red Pulp B Cell Lymphoma","volume":"9","author":"Verney","year":"2018","journal-title":"Oncotarget"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1182\/blood-2013-04-497271","article-title":"Bone Marrow Stroma CD40 Expression Correlates with Inflammatory Mast Cell Infiltration and Disease Progression in Splenic Marginal Zone Lymphoma","volume":"123","author":"Franco","year":"2014","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ni.2194","article-title":"B Cell-Helper Neutrophils Stimulate the Diversification and Production of Immunoglobulin in the Marginal Zone of the Spleen","volume":"13","author":"Puga","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1084\/jem.20161621","article-title":"Splenic Ly6Ghigh Mature and Ly6Gint Immature Neutrophils Contribute to Eradication of S. Pneumoniae","volume":"214","author":"Deniset","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1084\/jem.20170655","article-title":"Location in the Spleen Dictates the Function of Murine Neutrophils","volume":"214","author":"Scapini","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Patten, C.L., and Cutucache, C.E. (2016). Murine Models of Splenic Marginal Zone Lymphoma: A Role for Cav1?. Front. Oncol., 6.","DOI":"10.3389\/fonc.2016.00258"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological Analysis Reveals a PD-L1-Associated Microenvironmental Niche for Reed-Sternberg Cells in Hodgkin Lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3324\/haematol.2015.139493","article-title":"Role of the Tumor Microenvironment in Mature B-Cell Lymphoid Malignancies","volume":"101","author":"Fowler","year":"2016","journal-title":"Haematologica"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0012-1606(03)00136-2","article-title":"Netrins and DCC in the Guidance of Migrating Neural Crest-Derived Cells in the Developing Bowel and Pancreas","volume":"258","author":"Jiang","year":"2003","journal-title":"Dev. Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.semcancer.2015.07.004","article-title":"Microenvironment Abnormalities and Lymphomagenesis: Immunological Aspects","volume":"34","author":"Taylor","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1158\/1078-0432.CCR-09-2487","article-title":"A Unifying Microenvironment Model in Follicular Lymphoma: Outcome Is Predicted by Programmed Death-1-Positive, Regulatory, Cytotoxic, and Helper T Cells and Macrophages","volume":"16","author":"Wahlin","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1080\/21645515.2015.1129478","article-title":"Ipilimumab (Anti-Ctla-4 Mab) in the Treatment of Metastatic Melanoma: Effectiveness and Toxicity Management","volume":"12","author":"Savoia","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Meti, N., Esfahani, K., and Johnson, N. (2018). The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma. Cancers, 10.","DOI":"10.3390\/cancers10060204"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High Numbers of Tumor-Infiltrating Programmed Cell Death 1-Positive Regulatory Lymphocytes Are Associated with Improved Overall Survival in Follicular Lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1158\/1078-0432.CCR-19-0104","article-title":"High-Plex Predictive Marker Discovery for Melanoma Immunotherapy\u2013Treated Patients Using Digital Spatial Profiling","volume":"25","author":"Toki","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-18-0309","article-title":"Quantitative Spatial Profiling of PD-1\/PD-L1 Interaction and HLA-DR\/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma","volume":"24","author":"Johnson","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11899-018-0484-4","article-title":"Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma","volume":"13","author":"Hu","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/bs.apha.2021.01.002","article-title":"Review of immune checkpoint inhibitors in immuno-oncology","volume":"Volume 91","author":"Jacob","year":"2021","journal-title":"Advances in Pharmacology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3324\/haematol.2020.258426","article-title":"A Deep Molecular Response of Splenic Marginal Zone Lymphoma to Front-Line Checkpoint Blockade","volume":"106","author":"Miller","year":"2020","journal-title":"Haematologica"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41423-019-0228-y","article-title":"Inflamed Phenotype of Splenic Marginal Zone B-Cell Lymphomas with Expression of PD-L1 by Intratumoral Monocytes\/Macrophages and Dendritic Cells","volume":"16","author":"Soubeyran","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.humpath.2017.10.029","article-title":"Programmed Death-1 Ligands PD-L1 and PD-L2 Show Distinctive and Restricted Patterns of Expression in Lymphoma Subtypes","volume":"71","author":"Panjwani","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1182\/blood-2019-132211","article-title":"A Phase II Trial of Ibrutinib and PD-1 Blockade in Asymptomatic High Risk Chronic Lymphocytic Leukemia to Improve Immune Function","volume":"134","author":"Chavez","year":"2019","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Arruga, F., Gyau, B.B., Iannello, A., Vitale, N., Vaisitti, T., and Deaglio, S. (2020). Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051825"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.1002\/jcb.27890","article-title":"New Insight into BIRC3: A Novel Prognostic Indicator and a Potential Therapeutic Target for Liver Cancer","volume":"120","author":"Fu","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"ref_105","first-page":"837","article-title":"The Role of Oncogenic Notch2 Signaling in Cancer: A Novel Therapeutic Target","volume":"9","author":"Xiu","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/sj.leu.2403592","article-title":"Induction of Apoptosis by Proteasome Inhibitors in B-CLL Cells Is Associated with Downregulation of CD23 and Inactivation of Notch2","volume":"19","author":"Duechler","year":"2005","journal-title":"Leukemia"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/5\/297\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:57:30Z","timestamp":1760165850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/5\/297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":106,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["curroncol28050297"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28050297","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,6]]}}}